Alpibectir/Ethionamide - BioVersys/GSK
Alternative Names: AlpE; BVL-GSK-098/Ethionamide; BVL-GSK3729098/EthionamideLatest Information Update: 15 May 2026
At a glance
- Originator BioVersys; GlaxoSmithKline
- Developer BioVersys
- Class Alkenes; Amides; Antituberculars; Aza compounds; Ethers; Fluorinated hydrocarbons; Ketones; Pyridines; Small molecules; Spiro compounds
- Mechanism of Action Cell wall inhibitors; Transcription factor inhibitors
-
Orphan Drug Status
Yes - Tuberculosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Tubercular meningitis; Tuberculosis